Arca
Skip to content
Tools
Tools

Bronchiolitis

Drug research and approvals for bronchiolitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 119 studies of bronchiolitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 5 open orphan designations naming it.

  • Recruiting worldwide: 119
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 119 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

7 in phase 3, 5 in phase 2; from ChEMBL's drug indications, furthest stage reached for this condition
Dexamethasone
Phase 3 Glucocorticoid receptor agonist
Epinephrine
Phase 3 Adrenergic receptor agonist
Montelukast
Phase 3 Cysteinyl leukotriene receptor 1 antagonist
Furosemide
Phase 3 Sodium-(potassium)-chloride cotransporter 2 inhibitor
Nitric oxide
Phase 3 Soluble guanylate cyclase activator
Oxygen
Phase 3 Essential for cellular homeostasis
Cholecalciferol
Phase 2 Vitamin D receptor agonist
Albuterol
Phase 2 Beta-2 adrenergic receptor agonist
Fluticasone propionate
Phase 2 Glucocorticoid receptor agonist
Phenylephrine
Phase 2 Adrenergic receptor alpha-1 agonist
Nitazoxanide
Phase 2 Pyruvate:ferredoxin oxidoreductase inhibitor

How Its Trials Ended

379 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 97 whose ending is known, 29% met their primary endpoint, 23% missed it and 48% stopped early.

  • Completed, result not reported15340%
  • Ongoing6818%
  • Status unknown6116%
  • Met its primary endpoint287%
  • Stopped: other or unclear257%
  • Missed its primary endpoint226%
  • Stopped: enrollment or feasibility123%
  • Stopped: lack of efficacy31%
  • Stopped: sponsor or business decision31%
  • Stopped: funding31%
  • Stopped: safety10%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Dec 17, 2021A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of bi 1291583 qd over at least…Verducatib (bi 1291583)Boehringer Ingelheim (Canada) Ltd LteeClosed
Nov 12, 2019An open-label, single-arm, phase 1/2 study evaluating the safety and efficacy of itacitinib in participants with bronchiolitis obliterans syndrome following…Itacitinib (INCB039110)IncyteClosed
Jan 22, 2018A randomized controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitisdexamethasone/ epinephrineChildrens Hospital Of Eastern Ontario Research InstituteClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Dec 21, 2021SirolimusTreatment of Bronchiolitis Obliterans SyndromeAI Therapeutics, Inc.Designated
Aug 7, 2018Interleukin-1 receptor antagonist (IL-1Ra,…Treatment of Bronchiolitis ObliteransOnspira Therapeutics, Inc., a wholly owned subsidiary of Sumitomo Pharma America, Inc.Designated
Apr 10, 2017Recombinant human club cell proteinTreatment of bronchiolitis obliteransTrove Therapeutics, Inc.Designated
May 11, 2009Liposomal cyclosporineTreatment of bronchiolitis obliteransZambon S.p.A.Designated
Jun 24, 2008Liposomal cyclosporine for inhalationPrevention of bronchiolitis obliterans.Zambon S.p.A.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.